KR20180081812A - 허혈성 뇌졸중 치료용 조성물 및 방법 - Google Patents

허혈성 뇌졸중 치료용 조성물 및 방법 Download PDF

Info

Publication number
KR20180081812A
KR20180081812A KR1020187017549A KR20187017549A KR20180081812A KR 20180081812 A KR20180081812 A KR 20180081812A KR 1020187017549 A KR1020187017549 A KR 1020187017549A KR 20187017549 A KR20187017549 A KR 20187017549A KR 20180081812 A KR20180081812 A KR 20180081812A
Authority
KR
South Korea
Prior art keywords
compound
formula
cromolyn
stroke
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020187017549A
Other languages
English (en)
Korean (ko)
Inventor
데이빗 엘마레
Original Assignee
아즈테라피즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아즈테라피즈 인코포레이티드 filed Critical 아즈테라피즈 인코포레이티드
Publication of KR20180081812A publication Critical patent/KR20180081812A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020187017549A 2015-11-23 2016-11-23 허혈성 뇌졸중 치료용 조성물 및 방법 Withdrawn KR20180081812A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562258882P 2015-11-23 2015-11-23
US62/258,882 2015-11-23
PCT/US2016/063462 WO2017091644A1 (en) 2015-11-23 2016-11-23 Compositions and methods for treating ischemic stroke

Publications (1)

Publication Number Publication Date
KR20180081812A true KR20180081812A (ko) 2018-07-17

Family

ID=58764360

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187017549A Withdrawn KR20180081812A (ko) 2015-11-23 2016-11-23 허혈성 뇌졸중 치료용 조성물 및 방법

Country Status (9)

Country Link
US (2) US20180344682A1 (enExample)
EP (1) EP3380095B1 (enExample)
JP (1) JP2018538273A (enExample)
KR (1) KR20180081812A (enExample)
CN (1) CN108472275A (enExample)
AU (1) AU2016359674A1 (enExample)
CA (1) CA3005909A1 (enExample)
MX (1) MX390748B (enExample)
WO (1) WO2017091644A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP2911664B1 (en) 2012-10-25 2019-05-08 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CA3033079A1 (en) * 2016-08-31 2018-03-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
KR20210070232A (ko) 2017-07-20 2021-06-14 아즈테라피즈 인코포레이티드 크로몰린 나트륨 및 이부프로펜의 분말화된 제형
EP3720429A4 (en) * 2017-12-04 2021-09-15 The General Hospital Corporation COMPOSITIONS BASED ON CROMOGLICIC ACID AND RELATED PROCESSES
US20210059977A1 (en) * 2018-04-09 2021-03-04 The General Hospital Corporation Combination therapies for the treatment of amyotrophic lateral sclerosis and related disorders
CA3105392A1 (en) 2018-07-02 2020-01-09 The General Hospital Corporation Powdered formulations of cromolyn sodium and .alpha.-lactose
EP3893945A4 (en) 2018-12-10 2022-11-30 The General Hospital Corporation CROMOGLYC ESTERS AND THEIR USES
US12458622B2 (en) 2020-04-06 2025-11-04 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
WO2025235823A1 (en) * 2024-05-08 2025-11-13 The Johns Hopkins University Compositions and methods for treatment of neuronal injury and neurode generative disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071531A1 (en) * 2003-02-13 2004-08-26 Licentia Oy Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
EP1789057B1 (en) * 2004-08-30 2010-02-24 Seo Hong Yoo Neuroprotective effect of solubilized udca in focal ischemic model
US9925282B2 (en) * 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CN105061376A (zh) * 2009-01-29 2015-11-18 通用医疗公司 色甘酸衍生物以及成像和治疗的相关方法
SG173705A1 (en) * 2009-03-05 2011-09-29 Abbott Lab Il-17 binding proteins
TW201036972A (en) * 2009-03-11 2010-10-16 Plexxikon Inc Compounds and uses thereof
EP2911664B1 (en) * 2012-10-25 2019-05-08 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
JP2016534976A (ja) * 2013-05-23 2016-11-10 アズセラピーズ インコーポレイテッド クロモリンを送達する方法
AU2014340182B2 (en) * 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP3653207A1 (en) * 2014-02-10 2020-05-20 Respivant Sciences GmbH Mast cell stabilizers treatment for systemic disorders
CA3033079A1 (en) * 2016-08-31 2018-03-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases

Also Published As

Publication number Publication date
JP2018538273A (ja) 2018-12-27
MX2018006390A (es) 2019-02-14
US20180344682A1 (en) 2018-12-06
EP3380095A1 (en) 2018-10-03
EP3380095A4 (en) 2019-10-23
MX390748B (es) 2025-03-21
AU2016359674A1 (en) 2018-06-14
US20220125753A1 (en) 2022-04-28
EP3380095B1 (en) 2022-01-05
WO2017091644A1 (en) 2017-06-01
CN108472275A (zh) 2018-08-31
CA3005909A1 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
US20220125753A1 (en) Compositions and methods for treating ischemic stroke
US6376550B1 (en) Pharmaceutical compositions containing tramadol for migraine
TW201505634A (zh) 藥物戒斷之無毒治療方法
EP1265615A2 (de) Neue kombination nichtsedierender antihistaminika mit substanzen, die die leukotrienwirkung beeinflussen, zur behandlung der rhinitis/konjunktivitis
CA3025702A1 (en) Stable cannabinoid formulations
CN117377476B (zh) 治疗与化学疗法诱发的周围神经病变相关的疼痛
JP2020510675A (ja) ミトコンドリア起源のｒｏｓの産生の特異的阻害剤を使用した、薬物誘発ｑｔ間隔延長に関連するリスクの予防
JP2012510967A (ja) 肥満細胞媒介疾患を治療するための１−アミノ−アルキルシクロヘキサン誘導体
US20100055176A1 (en) Method of Treating Fibromyalgia or Associated Functional Symptoms of Fibromyalgia
CN1235545A (zh) 含有氯雷他定和减充血剂的用于治疗哮喘的组合物
US20060276495A1 (en) Treatment methods of nasal congestion and nasal obstruction
ES2534560T3 (es) Acetato de eslicarbazepina y su uso
JP6258264B2 (ja) ヒトの血小板レベルを増加させるための組成物および方法
KR20170012480A (ko) 당뇨병을 치료하기 위한 카페스톨
JPH0251885B2 (enExample)
KR20090024248A (ko) Ｃｘｃｒ2의 선택적 길항제 또는 ｃｘｃｒ1과 ｃｘｃｒ2 둘다의 선택적 길항제의 약제학적 제형 및 조성물, 및 염증성 질환을 치료하기 위한 이의 사용방법
Hartnett et al. Comparison of oral theophylline and salbutamol by inhalation in asthmatic patients
EP3326616A1 (en) Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current
EP0813878A1 (en) Lacrimation accelerating agent containing a serotonin ligand, especially aminoalkoxybibenzyl compounds
US20120028976A1 (en) Pharmacokinetically-based dosing regiments of a thrombin receptor antagonist
Cutler et al. Pharmacokinetics and pharmacodynamics of avitriptan in patients with migraine after oral dosing
EP4670737A1 (en) PHARMACEUTICAL PRODUCT FOR THE TREATMENT OR PREVENTION OF PERIPHERAL NEUROPATHY
WO2003000264A1 (en) Antihistamines for the treatment of nasal congestion and nasal obstruction
Yeung et al. PII‐66: Pharmacokinetics and hemodynamic effects of diltiazem in rats following single and repeated subcutaneous injection in vivo
HK1158984A (en) Use of dronedarone for the preparation of a medicament for the prevention of stroke or transient ischemic attack

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000